title: Overexpression of metastasis-associated protein 1 is significantly correlated with tumor angiogenesis and poor survival in patients with early-stage non-small cell lung cancer.
abstract: BACKGROUND
  The aims of this work are to detect the expression levels of metastasis-associated protein 1 (MTA1) in patients with early-stage non-small cell lung cancer (NSCLC), and to investigate the relationship of MTA1 protein with clinicopathologic factors, tumor angiogenesis, and prognosis.
  
  
  METHODS
  One hundred and two patients with pathologic stage I NSCLC who successfully underwent curative surgical resection were enrolled in this study. Immunohistochemical staining for MTA1 and CD34 was performed using the streptavidin-peroxidase method, and intratumoral microvessel density (MVD) was recorded by counting CD34-positive immunostained endothelial cells. All statistical analyses were performed with SPSS statistical software to determine the effects of MTA1 protein on clinicopathologic factors, tumor angiogenesis, and prognosis.
  
  
  RESULTS
  MTA1 protein overexpression was detected in 41 cases and was significantly associated with MVD (P = 0.008). MTA1 protein overexpression and high MVD were significantly associated with tumor relapse (P = 0.004 and 0.007) and poor 5-year disease-free survival (P = 0.001 and 0.004). Patients with MTA1 protein overexpression and high MVD had significantly poor overall survival (P = 0.005 and 0.043) and disease-specific survival (P = 0.006 and 0.031) at 5 years after operation. Multivariate analysis demonstrated that MTA1 protein overexpression was an independent prognosticator for unfavorable disease-free, overall, and disease-specific survival (P = 0.011, 0.024, and 0.046).
  
  
  CONCLUSIONS
  MTA1 protein overexpression is common in early-stage NSCLC and is significantly associated with tumor angiogenesis and poor survival. These findings suggest that MTA1 may have clinical potential as a promising predictor to identify individuals with poor prognostic potential and as a possible novel target molecule of antiangiogenic therapy for patients with early-stage NSCLC.
authors.affiliation: Department of Thoracic Surgery, Qi Lu Hospital, Shandong University, Jinan, Shandong Province, China.
authors.forename: Shu-Hai
authors.initials: SH
authors.lastname: Li
authors.forename: Hui
authors.initials: H
authors.lastname: Tian
authors.forename: Wei-Ming
authors.initials: WM
authors.lastname: Yue
authors.forename: Lin
authors.initials: L
authors.lastname: Li
authors.forename: Wen-Jun
authors.initials: WJ
authors.lastname: Li
authors.forename: Zhi-Tao
authors.initials: ZT
authors.lastname: Chen
authors.forename: Wen-Si
authors.initials: WS
authors.lastname: Hu
authors.forename: Ying-Chao
authors.initials: YC
authors.lastname: Zhu
authors.forename: Lei
authors.initials: L
authors.lastname: Qi
mesh_terms: D000230:Adenocarcinoma / Q000098:blood supply / Q000378:metabolism / Q000401:mortality*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002289:Carcinoma, Non-Small-Cell Lung / Q000098:blood supply / Q000378:metabolism / Q000401:mortality*; D002294:Carcinoma, Squamous Cell / Q000098:blood supply / Q000378:metabolism / Q000401:mortality*; D005260:Female; D005500:Follow-Up Studies; D006655:Histone Deacetylases / Q000378:metabolism*; D006801:Humans; D007124:Immunoenzyme Techniques; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009389:Neovascularization, Pathologic; D012097:Repressor Proteins / Q000378:metabolism*; D015996:Survival Rate; D015534:Trans-Activators; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; C089320:MTA1 protein, human; D012097:Repressor Proteins; D015534:Trans-Activators; D006655:Histone Deacetylases